Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: A Brief History Of Asset Swaps

This article was originally published in Scrip

Executive Summary

Even with the proposed acquisition of Allergan Plc by Pfizer Inc., 2015 was not so much the year of life science M&A or even the bursting of the biotech bubble but the rise in the asset-swapping imperative. The jury is almost certainly still out for this development amongst big pharmaceutical companies so unlike the pharmaceutical mega-merger there is at least one reason why we may continue to see asset swap transactions in 2016.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel